Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in Lung Transplant Patients

Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in Lung Transplant Patients

Published

News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow® Technology nebulizer.
 

Read the press release

Back to overview